Sinovac Biotech Ltd. (SVA)
| Previous close | 6.47 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 6.47 - 6.47 |
| 52-week range | 6.47 - 6.47 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 642.437M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 6.66 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.52 |
- Business Wire
Sinovac Amends Shareholder Rights Plan
BEIJING, February 21, 2024--Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025.
- Business Wire
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
BEIJING, January 18, 2024--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of Directors") unanimously determined that the partial tender offer (the "Tender Offer") by Alternative Liquidity Index LP ("Alternative Liquidity") to acquire up to 10,000,000 common shares of Sinovac (the "Shares") for $0.03 per share in cash (the "Offer Price") is NOT advisable and is NOT
- Business Wire
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
BEIJING, September 11, 2023--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection ("SA55 Injection") in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.
